IniciGrupsConversesMésTendències
Cerca al lloc
Aquest lloc utilitza galetes per a oferir els nostres serveis, millorar el desenvolupament, per a anàlisis i (si no has iniciat la sessió) per a publicitat. Utilitzant LibraryThing acceptes que has llegit i entès els nostres Termes de servei i política de privacitat. L'ús que facis del lloc i dels seus serveis està subjecte a aquestes polítiques i termes.

Resultats de Google Books

Clica una miniatura per anar a Google Books.

S'està carregant…

Bad Blood: Secrets and Lies in a Silicon Valley Startup (2018)

de John Carreyrou

Altres autors: Mira la secció altres autors.

MembresRessenyesPopularitatValoració mitjanaMencions
2,5661785,506 (4.31)93
"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--… (més)
S'està carregant…

Apunta't a LibraryThing per saber si aquest llibre et pot agradar.

No hi ha cap discussió a Converses sobre aquesta obra.

» Mira també 93 mencions

Anglès (176)  Suec (1)  Totes les llengües (177)
Es mostren 1-5 de 177 (següent | mostra-les totes)
I always wondered why is was so difficult to expose illegal business activity. Now I understand why. The pressure on the truth teller is intense. ( )
  addunn3 | Nov 6, 2023 |
Good book and a great story. It got a little monotonous and repetitive at times but I’m glad I read it. ( )
  kevindern | Oct 27, 2023 |
Coming to this book a bit after-the-fact (the two main protagonists were prosecuted a year ago), I was already biased against Elizabeth Holmes. I had really only been paying passing attention to the situation, thinking it just another 'tech" talking a good game, getting a lot of press and walking away with tons of money, enough to hire lawyers to sort out the mess.
Well, I got to page 25 and absolutely hated her and it became clearer and clearer as the book went on that this was a situation that went well beyond the typical Silicon Valley flash in the pan that came crashing down, this whole situation was outright fraud. Whether or not she is a diagnosed Sociopath, Ms Holmes managed to convince a number of very intelligent people that she was going to change the world for the better, all while having absolutely no concept on how to get her idea to work.
As an aside, the shear amount of employee turnover would give any business person and investor pause (it is comforting to see the number of people who left the company on moral grounds).
Towards the end of this horror show, I just couldn't help picturing in my mind Elizabeth Holmes jumping up and down in her cell complaining to all who would listen about how unfair this whole situation is. That the medical establishment and a muckraking journalist were just out to get her. It really is unfortunate that she'll be out of prison in a couple of years, I am convinced that she will not, ever, learn a lesson from this. ( )
  hhornblower | Oct 26, 2023 |
The nerve of some people! ( )
  fromthecomfychair | Oct 22, 2023 |
This is kickass writing. I listened to the audiobook and it read like a nail biting thriller. A simple story of how perceptions can cause so much illusions. More importantly, why founder-value fit is much more important than product-market fit. ( )
  Santhosh_Guru | Oct 19, 2023 |
Es mostren 1-5 de 177 (següent | mostra-les totes)
The author’s description of Holmes as a manic leader who turned coolly hostile when challenged is ripe material for a psychologist; Carreyrou wisely lets the evidence speak for itself. As presented here, Holmes harbored delusions of grandeur but couldn’t cope with the messy realities of bioengineering. Swathed in her own reality distortion field, she dressed in black turtlenecks to emulate her idol Jobs and preached that the Theranos device was “the most important thing humanity has ever built.” Employees were discouraged from questioning this cultish orthodoxy by her “ruthlessness” and her “culture of fear.” Secrecy was obsessive. Labs and doors were equipped with fingerprint scanners.
 

» Afegeix-hi altres autors

Nom de l'autorCàrrecTipus d'autorObra?Estat
John Carreyrouautor primaritotes les edicionscalculat
Damron, WillNarradorautor secundarialgunes edicionsconfirmat
Has d'iniciar sessió per poder modificar les dades del coneixement compartit.
Si et cal més ajuda, mira la pàgina d'ajuda del coneixement compartit.
Títol normalitzat
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Títol original
Títols alternatius
Data original de publicació
Gent/Personatges
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Llocs importants
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Esdeveniments importants
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Pel·lícules relacionades
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Epígraf
Dedicatòria
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
For Molly, Sebastian, Jack, and Francesca
Primeres paraules
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Tim Kemp had good news for his team.
Citacions
Darreres paraules
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
(Clica-hi per mostrar-ho. Compte: pot anticipar-te quin és el desenllaç de l'obra.)
Nota de desambiguació
Editor de l'editorial
Creadors de notes promocionals a la coberta
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
Llengua original
Informació del coneixement compartit en anglès. Modifica-la per localitzar-la a la teva llengua.
CDD/SMD canònics
LCC canònic

Referències a aquesta obra en fonts externes.

Wikipedia en anglès

Cap

"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--

No s'han trobat descripcions de biblioteca.

Descripció del llibre
Sumari haiku

Debats actuals

Cap

Cobertes populars

Dreceres

Valoració

Mitjana: (4.31)
0.5
1 10
1.5
2 7
2.5 1
3 79
3.5 32
4 318
4.5 69
5 382

Ets tu?

Fes-te Autor del LibraryThing.

 

Quant a | Contacte | LibraryThing.com | Privadesa/Condicions | Ajuda/PMF | Blog | Botiga | APIs | TinyCat | Biblioteques llegades | Crítics Matiners | Coneixement comú | 197,780,423 llibres! | Barra superior: Sempre visible